Pharmacogenetic Variability and Quality of Life in Adolescent Patients with Schizophrenia: The Impact of Metabolizer Status, Symptom Severity, and Adverse Reactions to Antipsychotic Treatment

CYP2D6 (NM vs reduced-function metabolizers, 2nd-generation antipsychotics)

CYP2D6 genotyping (NM vs RFM) in 47 adolescent schizophrenia patients on 2nd-generation antipsychotics: assessment of symptoms (PANSS), adverse effects (EPS, hyperprolactinemia) and quality of life (PQ-LES-Q) by metabolizer status

Prospective clinical study (n=47 adolescents, 14-18 years, DSM-5 schizophrenia) evaluating the impact of CYP2D6 metabolizer status on tolerability and quality of life under 2nd-generation antipsychotics. Reduced-function metabolizers (RFM) show more extrapyramidal side effects (EPS) and hyperprolactinemia, and significantly worse quality of life (PQ-LES-Q) than normal metabolizers (NM). CYP2D6 status explains part of interindividual tolerability variability, beyond symptom severity.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Pediatric psychiatric population: an angle often overlooked in PGx, even though antipsychotics are CPIC Level A CYP2D6 substrates. This study provides direct clinical evidence that preemptive CYP2D6 genotyping would improve drug and dose selection in adolescent schizophrenia. Integrate into pediatric psychiatric PGx panels.

CYP2D6 CPIC Level A antipsychotics +2; pediatric population (14-18 yrs, original angle) +2; QoL + ADR endpoints +2; J Clin Med +1